Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid neoadjuvant translational study in invasive prostate cancer
2009-014446-28Phase 2Active
- Sponsor
- Università Campus Bio-Medico di Roma
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zoledronic acid in prostate cancer (PCa), sponsored by Università Campus Bio-Medico di Roma. Primary endpoint: Increase in apoptotic markers. Started Dec 2009; status: active.
02
Drugs
zoledronic acid
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2009-014446-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014446-28.